Merus(MRUS)
搜索文档
Merus N.V. (MRUS) Investor Presentation - Slideshow
2022-05-25 03:05
Corporate Presentation May 2022 Disclaimer 2 This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the impact our Biclonics® and Triclonics® platforms can have on cancer, our ...
Merus (MRUS) Investor Presentation - Slideshow
2020-05-30 01:37
Merus Closing In On Cancer May 2020 Disclaimer 2 This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the impact our Biclonics® platform can have on cancer, our product candi ...
Merus (MRUS) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
2019-06-08 04:03
Merus Pioneering Bispecific Antibodies Ton Logtenberg, Founder President and Chief Executive Officer June 4, 2019 2 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements rega ...
Merus (MRUS) Investor Presentation - Slideshow
2019-03-13 02:36
Merus Pioneering Bispecific Antibodies MARCH 12, 2019 2 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the impact our Biclonics® platform can have on cancer, ...